Dr Joel Giblett
Dr Joel Giblett, Consultant Cardiologist
Responsibilities at LHCH
Consultant Cardiologist with a special interest in Interventional Cardiology
Area of Practice
Special Clinical Interests
Percutaneous Coronary Intervention
Cardioprotection in ischaemic heart disease, particularly through manipulation of metabolic targets. My research has particularly focused on the impact of glucagon-like peptide 1 on ventricular and coronary physiology during ischaemia.
I am currently involved in outcomes research for structural intervention in adult cardiac disease.
I am on the Editorial Board of JACC: Case Reports and BMC Cardiovascular Disorders
Current Membership of Professional Regional and National Bodies
British Cardiovascular Society (BCS)
British Cardiovascular Intervention Society (BCIS)
Royal College of Physicians of London
Why choose LHCH?
It is a well-respected national centre of excellence, with friendly staff providing great care for patients
Training and Education
I attend the University of Southampton medical school, obtaining first class honours in Biomedical Science (BSc), and graduating with a BM in 2007. I undertook Foundation Training and Core Medical Training in Wessex deanery, primarily at Poole and Royal Bournemouth Hospital, before transfering to Cambridge for Cardiology registrar training.
I was awarded a research fellowship at Royal Papworth Hospital and the University of Cambridge, investigating the role of the hormone GLP-1 in protecting the heart during heart attacks. I graduated with an MD in 2017 and completed my cardiology training in the East of England region.
I was awarded a BCIS International Fellowship and travelled to Royal Jubilee Hospital in British Columbia, Canada, for further training in PCI and TAVI. I returned to the UK and briefly undertook a locum consultant post at Royal Papworth Hospital prior to taking up my substantive position at LHCH.
I’m married with two small girls. I’m a long-suffering Arsenal fan, but will happily talk about or watch virtually any sport.
Giblett JP et al. Transcatheter treatment of postinfarct ventricular septal defects. Heart. 2020
Giblett JP. Does Impella Support Really Prevent Catastrophe? JACC: Case Reports. 2020
Klementowicz P, Giblett JP, Agrawal SKB, Shapiro LM, Calvert PA. A Giant Saphenous Vein Graft Aneurysm Treated with Percutaneous Closure. JACC: Case Reports 2019
Węglarz P, Spisak-Borowska K, Bochenek T, Konarska-Kuszewska E, Machowski J, Trusz-Gluza M, Bajor G, Mizia-Stec K, Giblett JP*, Calvert PA*. Impact of percutaneous patent foramen ovale closure on migraine headaches in patients with history of ischemic neurological events. Advances in Interventional Cardiology. 2020
Gimenez MR, Giblett JP. Editorial: Are Vasopressors an Enemy of the Coronary
Arteries? JACC: Case Reports. 2019.
Giblett JP et al. The role of Glucagon-Like Peptide 1 Loading on periprocedural myocardial infarction During elective PCI (GOLD-PCI study): a randomized, placebo-controlled trial. American Heart Journal. 2019
Orzalkiewicz M, Hodson J, Kwok CS, Ludman PF, Giblett JP, Sudhakar G, Doshi SN, Khan SQ, Kinnaird T, Hildick-Smith D, Townend JN, Mamas MA, Calvert PA. Comparison of Routine Versus Selective Glycoprotein IIb/IIIa Inhibitors Usage in Primary Percutaneous Coronary Intervention (from the British Cardiovascular Interventional Society). American Journal of Cardiology. 2019.
Giblett JP, Abdul-Samad O, Shapiro LM, Rana BS, Patrick A Calvert PA. Patent
Foramen Ovale Closure in 2019. Interventional Cardiology Review. 2019.
Giblett JP et al. Glucagon-Like Peptide-1–Mediated Cardioprotection Does Not Reduce Right Ventricular Stunning and Cumulative Ischemic Dysfunction After Coronary Balloon Occlusion. JACC: Basic to Translational Science. 2019.
Clarke SJ, Pettit S, Giblett JP, Zhao TX, Kydd AC, Albrechtsen NJW, Deacon CF,
Parameshwar J, Hoole SP. Effects of Acute GLP-1 Infusion on Pulmonary and Systemic Hemodynamics in Patients With Heart Failure: A Pilot Study. Clinical Therapeutics. 2018.
Flore V, Brown A, Giblett JP, Liou K, Cranley J, Hoole SP, West NEJ. Clinical outcomes of bioresorbable vascular scaffolds implanted with routine versus selective optical coherence tomography guidance: results from a single-center experience. Eurointervention. 2018
Giblett JP et al. Percutaneous management of paravalvular leaks. Nat Rev Cardiology. 2019.
Clarke SJ, Giblett JP, Yang L, Hubsch A, West NEJ, O’Sullivan M, Figg N, Bennett MR, Zhao TX, Wewer-Albrechtson NJ, Deacon CF, Cheriyan J, Hoole SP. GLP-1 is a Coronary Artery Specific Vasodilator in Humans. Journal of the American Heart Association. 2018.
Hoole SP, Hernández-Sánchez J, Brown AJ, Giblett JP, Bennett MR, West NEJ.
Prediction of postpercutaneous coronary intervention myocardial infarction: insights from intravascular imaging, coronary flow, and biomarker evaluation. Coronary artery disease. 2018
Brown AJ, Giblett JP, Bennett MR, West NEJ, Hoole SP. Anatomical plaque and vessel characteristics are associated with hemodynamic indices including fractional flow reserve and coronary flow reserve: A prospective exploratory intravascular ultrasound analysis. International Journal of Cardiology. 2017.
Axell RG*, Giblett JP*, et al. Stunning and Right Ventricular
Dysfunction is Induced by Coronary Balloon Occlusion and Rapid Pacing in Humans: Insights from Right Ventricular Conductance Catheter Studies. JAHA. e005820 Mar 2017.(*Joint first author)
Axell RG, White PA, Giblett JP, Williams LK, Rana BR, Klein AK, O’Sullivan M, Davies WR, Densem CG, Hoole SP. Rapid Pacing Induced Right Ventricular Dysfunction is Evident after Balloon Expandable Trans-femoral Aortic Valve Replacement. JACC. 2017
Ha FJ, Giblett JP, Nerlekar N, Cameron JD, Meredith IT, West NEJ, Brown AJ. Optical Coherence Tomography Guided Percutaneous Coronary Intervention. Heart, Lung and Circulation. 2017.
Giblett JP, Hoole SP. Remote Ischemic Conditioning in Elective PCI? Journal of
Cardiovascular Pharmacology and Therapeutics. 2017
Giblett JP, Brown AJ, Hoole SP, West NEJ. Early disarticulation of a Bioresorbable Vascular Scaffold: an underreported consequence of repeat imaging. Cardiovascular Intervention and Therapeutics. 2017.
Giblett JP, et al. Glucagon-like Peptide-1 derived cardioprotection does not utilize a KATP-channel dependent pathway: mechanistic insights from human supply and demand ischemia studies. Cardiovascular Diabetology. 2016
Giblett JP et al. Glucagon-like Peptide-1: a promising agent for cardioprotection during myocardial ischemia. JACC: Basic to Translational Science. 2016
Giblett JP et al. Implantation of bioresorbable vascular scaffolds following acute coronary syndrome is associated with reduced early neointimal growth and strut coverage. Eurointervention. 2016
Giblett JP, West NEJ, Hoole SP. Cardioprotection for Percutaneous Coronary
Intervention–Reperfusion Quality as well as Quantity. International Journal of Cardiology. 2014
McCormick LM, Brown AJ, Ring LS, Gajendragadkar PR, Dockrill SJ, Hansom SP, Giblett JP, Gilbert TJ, Hoole SP, West NE. Direct stenting is an independent predictor of improved survival in patients undergoing primary percutaneous coronary intervention for ST elevation myocardial infarction. European Heart Journal: Acute Cardiovascular Care. 2014
Kyriakou T, Pontefract D, Viturro E, Hodgkinson CP, Laxton RC, Bogari N, Cooper G, Davies M, Giblett JP, Day INM, Simpson IA, Albrecht C and Ye S. Functional polymorphism in ABCA1 influences age of symptom onset in coronary artery disease patients. Human Molecular Genetics. 2007